Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Pegram

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Gynecologic Oncology|December 13, 2002
A human ovarian carcinoma murine xenograft model useful for preclinical trialsJohn C Elkas, Rae Lynn Baldwin, Mark Pegram, et al.
NPJ Breast Cancer|June 28, 2023
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancerGiuseppe Curigliano, Rebecca Dent, Antonio Llombart-Cussac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2020
Understanding the Role of Comparative Clinical Studies in the Development of Oncology BiosimilarsJustin Stebbing, Paul N Mainwaring, Giuseppe Curigliano, et al.
Clinical Breast Cancer|March 30, 2021
Advances in Therapeutic Approaches for Triple-Negative Breast CancerReshma Mahtani, Muaiad Kittaneh, Kevin Kalinsky, et al.
The International Journal of Biochemistry & Cell Biology|December 9, 2015
Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancerJunjun Liu, Xiaosong Chen, Toby Ward, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2009
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumorsMichael B Jameson, Danny Rischin, Mark Pegram, et al.
Therapeutic Advances in Medical Oncology|August 14, 2023
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancerMark Pegram, Richard Pietras, Chau T Dang, et al.
Cancer Research|July 20, 2006
Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivoLori Jerome, Nezha Alami, Sylvie Belanger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2021
Reply to J. Wei et alNancy U Lin, Mark Pegram, Solmaz Sahebjam, et al.
JCI Insight|February 28, 2020
Immune cell repertoires in breast cancer patients after adjuvant chemotherapyClaire E Gustafson, Rohit Jadhav, Wenqiang Cao, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Gynecologic Oncology|December 13, 2002
A human ovarian carcinoma murine xenograft model useful for preclinical trialsJohn C Elkas, Rae Lynn Baldwin, Mark Pegram, et al.
NPJ Breast Cancer|June 28, 2023
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancerGiuseppe Curigliano, Rebecca Dent, Antonio Llombart-Cussac, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2020
Understanding the Role of Comparative Clinical Studies in the Development of Oncology BiosimilarsJustin Stebbing, Paul N Mainwaring, Giuseppe Curigliano, et al.
Clinical Breast Cancer|March 30, 2021
Advances in Therapeutic Approaches for Triple-Negative Breast CancerReshma Mahtani, Muaiad Kittaneh, Kevin Kalinsky, et al.
The International Journal of Biochemistry & Cell Biology|December 9, 2015
Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancerJunjun Liu, Xiaosong Chen, Toby Ward, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2009
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumorsMichael B Jameson, Danny Rischin, Mark Pegram, et al.
Therapeutic Advances in Medical Oncology|August 14, 2023
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancerMark Pegram, Richard Pietras, Chau T Dang, et al.
Cancer Research|July 20, 2006
Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivoLori Jerome, Nezha Alami, Sylvie Belanger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2021
Reply to J. Wei et alNancy U Lin, Mark Pegram, Solmaz Sahebjam, et al.
JCI Insight|February 28, 2020
Immune cell repertoires in breast cancer patients after adjuvant chemotherapyClaire E Gustafson, Rohit Jadhav, Wenqiang Cao, et al.
Pageof 7